Absorption and disposition of bromate in F344 rats

Richard J. Bull, Narendrababu Kolisetty, Xiaoling Zhang, Srinivasa Muralidhara, Oscar Quiñones, Kok Yong Lim, Zhongxian Guo, Joseph A. Cotruvo, Jeffrey W. Fisher, Xiaoxia Yang, Don Delker, Shane A Snyder, Brian S. Cummings

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bromate (BrO3-) is a ubiquitous by-product of using ozone to disinfect water containing bromide (Br-). The reactivity of BrO3- with biological reductants suggests that its systemic absorption and distribution to target tissues may display non-linear behavior as doses increase. The intent of this study is to determine the extent to which BrO3- is systemically bioavailable via oral exposure and broadly identify its pathways of degradation. In vitro experiments of BrO3- degradation in rat blood indicate a rapid initial degradation immediately upon addition that is >98% complete at concentrations up to 66μM in blood. As initial concentrations are increased, progressively lower fractions are lost prior to the first measurement. Secondary to this initial loss, a slower and predictable first order degradation rate was observed (10%/min). Losses during both phases were accompanied by increases in Br- concentrations indicating that the loss of BrO3- was due to its reduction. In vivo experiments were conducted using doses of BrO3- ranging from 0.077 to 15.3mg/kg, administered intravenously (IV) or orally (gavage) to female F344 rats. The variable nature and uncertain source of background concentrations of BrO3- limited derivation of terminal half-lives, but the initial half-life was approximately 10min for all dose groups. The area under the curve (AUC) and peak concentrations (Ct=5') were linearly related to IV dose up to 0.77mg/kg; however, disproportionate increases in the AUC and Ct=5' and a large decrease in the volume of distribution was observed when IV doses of 1.9 and 3.8mg/kg were administered. The average terminal half-life of BrO3- from oral administration was 37min, but this was influenced by background levels of BrO3- at lower doses. With oral doses, the AUC and Cmax increased linearly with dose up to 15.3mgBrO3-/kg. BrO3- appeared to be 19-25% bioavailable without an obvious dose-dependency between 0.077 and 1.9mg/kg. The urinary elimination of BrO3- and Br- was measured from female F344 rats for four days following administration of single doses of 8.1mgKBrO3/kg and for 15 days after a single dose of 5.0mgKBr/kg. BrO3- elimination was detected over the first 12h, but Br- elimination from BrO3- over the first 48h was 18% lower than expected based on that eliminated from an equimolar dose of Br- (15.5±1.6 vs. 18.8±1.2μmol/kg, respectively). The cumulative excretion of Br- from KBr vs. KBrO3 was equivalent 72h after administration. The recovery of unchanged administered BrO3- in the urine ranged between 6.0 and 11.3% (creatinine corrected) on the 27th day of treatment with concentrations of KBrO3 of 15, 60, and 400mg/L of drinking water. The recovery of total urinary bromine as Br-+BrO3- ranged between 61 and 88%. An increase in the fraction of the daily BrO3- dose recovered in the urine was observed at the high dose to both sexes. The deficit in total bromine recovery raises the possibility that some brominated biochemicals may be produced in vivo and more slowly metabolized and eliminated. This was supported by measurements of dose-dependent increases of total organic bromine (TOBr) that was eliminated in the urine. The role these organic by-products play in BrO3--induced cancer remains to be established.

Original languageEnglish (US)
Pages (from-to)83-91
Number of pages9
JournalToxicology
Volume300
Issue number1-2
DOIs
StatePublished - Oct 9 2012
Externally publishedYes

Fingerprint

Bromates
Inbred F344 Rats
Bromides
Rats
Bromine
Area Under Curve
Degradation
Urine
Recovery
Byproducts
Half-Life
Blood
Ozone
Reducing Agents
Drinking Water
Oral Administration
Creatinine
Experiments
Tissue
Water

Keywords

  • Absorption
  • Bromate
  • Disposition
  • Rat
  • Reaction products

ASJC Scopus subject areas

  • Toxicology

Cite this

Bull, R. J., Kolisetty, N., Zhang, X., Muralidhara, S., Quiñones, O., Lim, K. Y., ... Cummings, B. S. (2012). Absorption and disposition of bromate in F344 rats. Toxicology, 300(1-2), 83-91. https://doi.org/10.1016/j.tox.2012.06.002

Absorption and disposition of bromate in F344 rats. / Bull, Richard J.; Kolisetty, Narendrababu; Zhang, Xiaoling; Muralidhara, Srinivasa; Quiñones, Oscar; Lim, Kok Yong; Guo, Zhongxian; Cotruvo, Joseph A.; Fisher, Jeffrey W.; Yang, Xiaoxia; Delker, Don; Snyder, Shane A; Cummings, Brian S.

In: Toxicology, Vol. 300, No. 1-2, 09.10.2012, p. 83-91.

Research output: Contribution to journalArticle

Bull, RJ, Kolisetty, N, Zhang, X, Muralidhara, S, Quiñones, O, Lim, KY, Guo, Z, Cotruvo, JA, Fisher, JW, Yang, X, Delker, D, Snyder, SA & Cummings, BS 2012, 'Absorption and disposition of bromate in F344 rats', Toxicology, vol. 300, no. 1-2, pp. 83-91. https://doi.org/10.1016/j.tox.2012.06.002
Bull RJ, Kolisetty N, Zhang X, Muralidhara S, Quiñones O, Lim KY et al. Absorption and disposition of bromate in F344 rats. Toxicology. 2012 Oct 9;300(1-2):83-91. https://doi.org/10.1016/j.tox.2012.06.002
Bull, Richard J. ; Kolisetty, Narendrababu ; Zhang, Xiaoling ; Muralidhara, Srinivasa ; Quiñones, Oscar ; Lim, Kok Yong ; Guo, Zhongxian ; Cotruvo, Joseph A. ; Fisher, Jeffrey W. ; Yang, Xiaoxia ; Delker, Don ; Snyder, Shane A ; Cummings, Brian S. / Absorption and disposition of bromate in F344 rats. In: Toxicology. 2012 ; Vol. 300, No. 1-2. pp. 83-91.
@article{4dc090d5c5e34a189652f3e819e85c0d,
title = "Absorption and disposition of bromate in F344 rats",
abstract = "Bromate (BrO3-) is a ubiquitous by-product of using ozone to disinfect water containing bromide (Br-). The reactivity of BrO3- with biological reductants suggests that its systemic absorption and distribution to target tissues may display non-linear behavior as doses increase. The intent of this study is to determine the extent to which BrO3- is systemically bioavailable via oral exposure and broadly identify its pathways of degradation. In vitro experiments of BrO3- degradation in rat blood indicate a rapid initial degradation immediately upon addition that is >98{\%} complete at concentrations up to 66μM in blood. As initial concentrations are increased, progressively lower fractions are lost prior to the first measurement. Secondary to this initial loss, a slower and predictable first order degradation rate was observed (10{\%}/min). Losses during both phases were accompanied by increases in Br- concentrations indicating that the loss of BrO3- was due to its reduction. In vivo experiments were conducted using doses of BrO3- ranging from 0.077 to 15.3mg/kg, administered intravenously (IV) or orally (gavage) to female F344 rats. The variable nature and uncertain source of background concentrations of BrO3- limited derivation of terminal half-lives, but the initial half-life was approximately 10min for all dose groups. The area under the curve (AUC) and peak concentrations (Ct=5') were linearly related to IV dose up to 0.77mg/kg; however, disproportionate increases in the AUC and Ct=5' and a large decrease in the volume of distribution was observed when IV doses of 1.9 and 3.8mg/kg were administered. The average terminal half-life of BrO3- from oral administration was 37min, but this was influenced by background levels of BrO3- at lower doses. With oral doses, the AUC and Cmax increased linearly with dose up to 15.3mgBrO3-/kg. BrO3- appeared to be 19-25{\%} bioavailable without an obvious dose-dependency between 0.077 and 1.9mg/kg. The urinary elimination of BrO3- and Br- was measured from female F344 rats for four days following administration of single doses of 8.1mgKBrO3/kg and for 15 days after a single dose of 5.0mgKBr/kg. BrO3- elimination was detected over the first 12h, but Br- elimination from BrO3- over the first 48h was 18{\%} lower than expected based on that eliminated from an equimolar dose of Br- (15.5±1.6 vs. 18.8±1.2μmol/kg, respectively). The cumulative excretion of Br- from KBr vs. KBrO3 was equivalent 72h after administration. The recovery of unchanged administered BrO3- in the urine ranged between 6.0 and 11.3{\%} (creatinine corrected) on the 27th day of treatment with concentrations of KBrO3 of 15, 60, and 400mg/L of drinking water. The recovery of total urinary bromine as Br-+BrO3- ranged between 61 and 88{\%}. An increase in the fraction of the daily BrO3- dose recovered in the urine was observed at the high dose to both sexes. The deficit in total bromine recovery raises the possibility that some brominated biochemicals may be produced in vivo and more slowly metabolized and eliminated. This was supported by measurements of dose-dependent increases of total organic bromine (TOBr) that was eliminated in the urine. The role these organic by-products play in BrO3--induced cancer remains to be established.",
keywords = "Absorption, Bromate, Disposition, Rat, Reaction products",
author = "Bull, {Richard J.} and Narendrababu Kolisetty and Xiaoling Zhang and Srinivasa Muralidhara and Oscar Qui{\~n}ones and Lim, {Kok Yong} and Zhongxian Guo and Cotruvo, {Joseph A.} and Fisher, {Jeffrey W.} and Xiaoxia Yang and Don Delker and Snyder, {Shane A} and Cummings, {Brian S.}",
year = "2012",
month = "10",
day = "9",
doi = "10.1016/j.tox.2012.06.002",
language = "English (US)",
volume = "300",
pages = "83--91",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Absorption and disposition of bromate in F344 rats

AU - Bull, Richard J.

AU - Kolisetty, Narendrababu

AU - Zhang, Xiaoling

AU - Muralidhara, Srinivasa

AU - Quiñones, Oscar

AU - Lim, Kok Yong

AU - Guo, Zhongxian

AU - Cotruvo, Joseph A.

AU - Fisher, Jeffrey W.

AU - Yang, Xiaoxia

AU - Delker, Don

AU - Snyder, Shane A

AU - Cummings, Brian S.

PY - 2012/10/9

Y1 - 2012/10/9

N2 - Bromate (BrO3-) is a ubiquitous by-product of using ozone to disinfect water containing bromide (Br-). The reactivity of BrO3- with biological reductants suggests that its systemic absorption and distribution to target tissues may display non-linear behavior as doses increase. The intent of this study is to determine the extent to which BrO3- is systemically bioavailable via oral exposure and broadly identify its pathways of degradation. In vitro experiments of BrO3- degradation in rat blood indicate a rapid initial degradation immediately upon addition that is >98% complete at concentrations up to 66μM in blood. As initial concentrations are increased, progressively lower fractions are lost prior to the first measurement. Secondary to this initial loss, a slower and predictable first order degradation rate was observed (10%/min). Losses during both phases were accompanied by increases in Br- concentrations indicating that the loss of BrO3- was due to its reduction. In vivo experiments were conducted using doses of BrO3- ranging from 0.077 to 15.3mg/kg, administered intravenously (IV) or orally (gavage) to female F344 rats. The variable nature and uncertain source of background concentrations of BrO3- limited derivation of terminal half-lives, but the initial half-life was approximately 10min for all dose groups. The area under the curve (AUC) and peak concentrations (Ct=5') were linearly related to IV dose up to 0.77mg/kg; however, disproportionate increases in the AUC and Ct=5' and a large decrease in the volume of distribution was observed when IV doses of 1.9 and 3.8mg/kg were administered. The average terminal half-life of BrO3- from oral administration was 37min, but this was influenced by background levels of BrO3- at lower doses. With oral doses, the AUC and Cmax increased linearly with dose up to 15.3mgBrO3-/kg. BrO3- appeared to be 19-25% bioavailable without an obvious dose-dependency between 0.077 and 1.9mg/kg. The urinary elimination of BrO3- and Br- was measured from female F344 rats for four days following administration of single doses of 8.1mgKBrO3/kg and for 15 days after a single dose of 5.0mgKBr/kg. BrO3- elimination was detected over the first 12h, but Br- elimination from BrO3- over the first 48h was 18% lower than expected based on that eliminated from an equimolar dose of Br- (15.5±1.6 vs. 18.8±1.2μmol/kg, respectively). The cumulative excretion of Br- from KBr vs. KBrO3 was equivalent 72h after administration. The recovery of unchanged administered BrO3- in the urine ranged between 6.0 and 11.3% (creatinine corrected) on the 27th day of treatment with concentrations of KBrO3 of 15, 60, and 400mg/L of drinking water. The recovery of total urinary bromine as Br-+BrO3- ranged between 61 and 88%. An increase in the fraction of the daily BrO3- dose recovered in the urine was observed at the high dose to both sexes. The deficit in total bromine recovery raises the possibility that some brominated biochemicals may be produced in vivo and more slowly metabolized and eliminated. This was supported by measurements of dose-dependent increases of total organic bromine (TOBr) that was eliminated in the urine. The role these organic by-products play in BrO3--induced cancer remains to be established.

AB - Bromate (BrO3-) is a ubiquitous by-product of using ozone to disinfect water containing bromide (Br-). The reactivity of BrO3- with biological reductants suggests that its systemic absorption and distribution to target tissues may display non-linear behavior as doses increase. The intent of this study is to determine the extent to which BrO3- is systemically bioavailable via oral exposure and broadly identify its pathways of degradation. In vitro experiments of BrO3- degradation in rat blood indicate a rapid initial degradation immediately upon addition that is >98% complete at concentrations up to 66μM in blood. As initial concentrations are increased, progressively lower fractions are lost prior to the first measurement. Secondary to this initial loss, a slower and predictable first order degradation rate was observed (10%/min). Losses during both phases were accompanied by increases in Br- concentrations indicating that the loss of BrO3- was due to its reduction. In vivo experiments were conducted using doses of BrO3- ranging from 0.077 to 15.3mg/kg, administered intravenously (IV) or orally (gavage) to female F344 rats. The variable nature and uncertain source of background concentrations of BrO3- limited derivation of terminal half-lives, but the initial half-life was approximately 10min for all dose groups. The area under the curve (AUC) and peak concentrations (Ct=5') were linearly related to IV dose up to 0.77mg/kg; however, disproportionate increases in the AUC and Ct=5' and a large decrease in the volume of distribution was observed when IV doses of 1.9 and 3.8mg/kg were administered. The average terminal half-life of BrO3- from oral administration was 37min, but this was influenced by background levels of BrO3- at lower doses. With oral doses, the AUC and Cmax increased linearly with dose up to 15.3mgBrO3-/kg. BrO3- appeared to be 19-25% bioavailable without an obvious dose-dependency between 0.077 and 1.9mg/kg. The urinary elimination of BrO3- and Br- was measured from female F344 rats for four days following administration of single doses of 8.1mgKBrO3/kg and for 15 days after a single dose of 5.0mgKBr/kg. BrO3- elimination was detected over the first 12h, but Br- elimination from BrO3- over the first 48h was 18% lower than expected based on that eliminated from an equimolar dose of Br- (15.5±1.6 vs. 18.8±1.2μmol/kg, respectively). The cumulative excretion of Br- from KBr vs. KBrO3 was equivalent 72h after administration. The recovery of unchanged administered BrO3- in the urine ranged between 6.0 and 11.3% (creatinine corrected) on the 27th day of treatment with concentrations of KBrO3 of 15, 60, and 400mg/L of drinking water. The recovery of total urinary bromine as Br-+BrO3- ranged between 61 and 88%. An increase in the fraction of the daily BrO3- dose recovered in the urine was observed at the high dose to both sexes. The deficit in total bromine recovery raises the possibility that some brominated biochemicals may be produced in vivo and more slowly metabolized and eliminated. This was supported by measurements of dose-dependent increases of total organic bromine (TOBr) that was eliminated in the urine. The role these organic by-products play in BrO3--induced cancer remains to be established.

KW - Absorption

KW - Bromate

KW - Disposition

KW - Rat

KW - Reaction products

UR - http://www.scopus.com/inward/record.url?scp=84863813101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863813101&partnerID=8YFLogxK

U2 - 10.1016/j.tox.2012.06.002

DO - 10.1016/j.tox.2012.06.002

M3 - Article

VL - 300

SP - 83

EP - 91

JO - Toxicology

JF - Toxicology

SN - 0300-483X

IS - 1-2

ER -